The two companies have been involved in recent licensing deals.
ApexOnco Front Page
Recent articles
ASCO looms, while FDA decisions are due on Enhertu and Inqovi.
New pivotal trials of HRS-8080 are planned in first-line and adjuvant breast cancer.
After Genmab’s exit two more ADCs enter human trials.
A new phase 3, Manifest-3, will start in April to support US filing.
The company takes a PD-L1 x VEGF asset into phase 3.
Intismeran autogene’s Interpath-001 trial reads out this year.
New first-in-human study initiations feature yet more in vivo Car assets.
